Methods of treating disorders using CSFIR inhibitors

Abstract

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

The invention claimed is: 
     
         1 . A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound represented by: 
       
         
           
           
               
               
           
         
         and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient about 2 mg to about 60 mg of the compound once a day, twice daily, every other day, once a week, twice weekly, or three times a week. 
       
     
     
         2 . The method of  claim 1 , wherein the tenosynovial giant cell tumor is localized. 
     
     
         3 . The method of  claim 1 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 
     
     
         4 . The method of  claim 1 , wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient about 5 mg to about 30 mg of the compound once a day, twice daily, every other day, once a week, twice weekly, or three times a week. 
     
     
         5 . The method of  claim 1 , wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient about 30 mg of the compound twice weekly. 
     
     
         6 . The method of  claim 1 , comprising administering to the patient the composition twice weekly for about 3 months. 
     
     
         7 . The method of  claim 1 , comprising administering to the patient the composition twice weekly for about 6 months. 
     
     
         8 . The method of  claim 1 , comprising administering to the patient the composition twice weekly for about 1 year. 
     
     
         9 . The method of  claim 1 , comprising administering to the patient the composition twice weekly for about 2 years. 
     
     
         10 . The method of  claim 1 , wherein the pharmaceutical composition is administered to the patient as a neo-adjuvant. 
     
     
         11 . The method of  claim 1 , wherein the pharmaceutical composition is administered to the patient as an adjuvant. 
     
     
         12 . A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound represented by: 
       
         
           
           
               
               
           
         
         and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient 30 mg of the compound twice weekly. 
       
     
     
         13 . The method of  claim 12 , wherein the tenosynovial giant cell tumor is localized. 
     
     
         14 . The method of  claim 12 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 
     
     
         15 . The method of  claim 12 , comprising administering to the patient the composition twice weekly for about 3 months. 
     
     
         16 . The method of  claim 12 , comprising administering to the patient the composition twice weekly for about 6 months. 
     
     
         17 . The method of  claim 12 , comprising administering to the patient the composition twice weekly for about 1 year. 
     
     
         18 . The method of  claim 12 , comprising administering to the patient the composition twice weekly for about 2 years. 
     
     
         19 . The method of  claim 12 , wherein the pharmaceutical composition is administered to the patient as a neo-adjuvant. 
     
     
         20 . The method of  claim 12 , wherein the pharmaceutical composition is administered to the patient as an adjuvant. 
     
     
         21 . A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound represented by: 
       
         
           
           
               
               
           
         
         and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient a therapeutically effective amount of the compound. 
       
     
     
         22 . The method of  claim 21 , wherein the tenosynovial giant cell tumor is localized. 
     
     
         23 . The method of  claim 21 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 
     
     
         24 . The method of  claim 21 , comprising administering to the patient the composition twice weekly for about 3 months. 
     
     
         25 . The method of  claim 21 , comprising administering to the patient the composition twice weekly for about 6 months. 
     
     
         26 . The method of  claim 21 , comprising administering to the patient the composition twice weekly for about 1 year. 
     
     
         27 . The method of  claim 21 , comprising administering to the patient the composition twice weekly for about 2 years. 
     
     
         28 . The method of  claim 21 , wherein the pharmaceutical composition is administered to the patient as a neo-adjuvant. 
     
     
         29 . The method of  claim 21 , wherein the pharmaceutical composition is administered to the patient as an adjuvant.